If you have been reading about DAC and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-10-24. Numbers and descriptions here follow the published literature rather than marketing material.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
| Property | Value | Notes |
|---|---|---|
| Duration with linker | Several days | Reported in early human work |
| Duration without linker | Tens of minutes | Short plasma residence |
| Albumin attachment site | Cysteine-34 | Covalent maleimide reaction |
| Primary receptor | Pituitary GHRH receptor | Stimulates growth hormone release |
| Downstream marker | Insulin-like growth factor 1 | Indirect measure of activity |
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
The samples were originally taken to test for preventable diseases, but with the advance in genomic sequencing technologies many samples are being kept for DNA identification and research, increasing the possibility that more children will be opted out of newborn screening from parents who see the kept samples as a form of research done on their child.
== History == The initiative was established in 2006 through a tripartite collaboration involving Cartier (jeweler), the international management consulting firm McKinsey & Company, and the INSEAD international business school. The program was designed to target discrepancies in international venture capital, where women entrepreneurs encounter substantial barriers in closing early-stage seed round funding. Over its two decades of operation, the program expanded from its foundational baseline of five regional categories to nine distinct geographic regions. In 2021, the initiative introduced its first thematic categories to incorporate technical innovations outside of regional boundaries. To mark its 2 decade anniversary in 2026, the program relocated its annual awards summit to Bangkok, Thailand, selecting a cohort of 30 global fellows.
=== Flavour === A portion of the distinct flavour comes from lipolysis (breakdown of fat). The metabolism of the blue mold further breaks down fatty acids to form ketones to give blue cheese a richer flavour and aroma.
=== Other fields === Welfare economics studies the influence of economic activity on well-being. One of its primary goals is to develop standards for evaluating and choosing between competing policy proposals based on their potential benefit to well-being. This field uses metrics such as distribution of income, gross domestic product, consumer surplus, and compensating variation. For example, distributing income more equally is usually beneficial for well-being but needs to be balanced against potential negative side effects, such as a decline in productivity. The economics of happiness, a closely related field, focuses specifically on the connection between economic phenomena and individual happiness. One of its findings is the Easterlin paradox: within a given country, people with higher incomes tend to be happier than those with lower income, yet overall happiness does not trend upward as the average income of everyone increases.
Sources: en.wikipedia.org
Repeated heroin use changes the physical structure and physiology of the brain, creating long-term imbalances in neuronal and hormonal systems that are not easily reversed. Studies have shown some deterioration of the brain's white matter due to heroin use, which may affect decision-making abilities, the ability to regulate behavior, and responses to stressful situations. Heroin also produces profound degrees of tolerance and physical dependence. Tolerance occurs when more and more of the drug is required to achieve the same effects. With physical dependence, the body adapts to the presence of the drug, and withdrawal symptoms occur if use is reduced abruptly.
== Mechanism in the trp operon == The proposed mechanism of how this mRNA secondary structure and the trp leader peptide could regulate transcription of the trp biosynthetic enzymes includes the following.
=== Fibromyalgia === Studies have also shown paroxetine "appears to be well-tolerated and improve the overall symptomatology in patients with fibromyalgia", but is less robust in helping with the pain involved.
== Research == Remdesivir was originally created and developed by Gilead Sciences in 2009, to treat hepatitis C and respiratory syncytial virus (RSV). It did not work against hepatitis C or RSV, but was then repurposed and studied as a potential treatment for Ebola virus disease and Marburg virus infections. According to the Czech News Agency, this new line of research was carried out under the direction of scientist Tomáš Cihlář. A collaboration of researchers from the Centers for Disease Control and Prevention (CDC) and Gilead Sciences subsequently discovered that remdesivir had antiviral activity in vitro against multiple filoviruses, pneumoviruses, paramyxoviruses, and coronaviruses. Preclinical and clinical research and development was done in collaboration between Gilead Sciences and various US government agencies and academic institutions. During the mid-2010s, the Mintz Levin law firm prosecuted various patent applications for remdesivir on behalf of Gilead Sciences before the United States Patent and Trademark Office (USPTO). The USPTO granted two patents on remdesivir to Gilead Sciences on 9 April 2019: one for filoviruses, and one which covered both arenaviruses and coronaviruses.
=== Partnerships and investments from US companies === Also in July, the UK government signed a deal with OpenAI to use its products in public services to increase productivity. As part of the 2025 Tech Prosperity Deal between the UK and the US, several American companies are investing tens of billions of pounds in British AI infrastructure.
Sources: en.wikipedia.org
== Life and physiology == At birth, earthworms emerge small but fully formed, lacking only their sex structures which develop in about 60 to 90 days. They attain full size in about one year. Scientists predict that the potential lifespan under field conditions is four to eight years, while the actual lifespan is probably no more than a few months because of intense predation and environmental hazards.
=== Engine === Chainsaw engines are traditionally either a two-stroke single-cylinder gasoline (petrol) internal combustion engine (usually with a cylinder volume of 30 to 120 cc) or an electric motor driven by a battery or electric power cord. In a petrol chainsaw, fuel is generally supplied to the engine by a carburetor at the intake. Two-stroke engines have been preferred for chainsaws due to their higher power-to-weight ratio and simplicity. Hydraulic power may be used for chainsaws for underwater use. To allow use in any orientation, modern gasoline chainsaws use a diaphragm carburetor, which draws fuel from the tank using the alternating pressure differential within the crankcase. Early engines used carburetors with gravity fed float chambers, which caused the engine to stall when tilted. The carburetor may need to be adjusted to maintain an appropriate idle speed and air-fuel ratio, such as when moving to a higher/lower altitude or as the air filter clogs. Carburetors are adjusted either by the operator or, in some saws, automatically by an electronic control unit. To prevent vibration induced injury and reduce user fatigue, saws generally have an anti-vibration system to physically decouple the handles from the engine and bar. This is achieved by constructing the saw in two pieces, connected by springs or rubber in the same way an automobile suspension isolates the chassis from the wheels and road. In cold weather, carburetor icing can occur, so many saws have a vent between the cylinders and carburetor which may be opened to allow hot air to pass.
The Hok/sok system a post-segregational killing system of the plasmid, toxin-antitoxin system hok: encodes a toxin that kills cells without the plasmid. sok: short anti-sense RNA that inhibits hok mRNA translation in plasmid carrying cells.
=== Medications === A number of treatments have been investigated in the past for IPF, including interferon gamma-1β, bosentan, ambrisentan, and anticoagulants, but these are no longer considered effective treatment options. Many of these earlier studies were based on the hypothesis that IPF is an inflammatory disorder.
== History == The concept of fatty acid (acide gras) was introduced in 1813 by Michel Eugène Chevreul, though he initially used some variant terms: graisse acide and acide huileux ("acid fat" and "oily acid").
Sources: en.wikipedia.org
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.
The group is intended to alter distribution and persistence, not receptor engagement. The peptide portion still binds the pituitary receptor, so the primary difference is duration rather than potency.
Not firmly. Early reports describe several days for the extended form, but independent confirmations are sparse, and values vary with assay method and study design.
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.